What is Manus Bio?
Manus Bio operates at the intersection of synthetic biology and industrial manufacturing, specializing in the production of high-value natural products. The company utilizes rapid biological advancements to synthesize ingredients essential for the flavor, fragrance, food, and pharmaceutical industries. By recreating natural processes through sophisticated fermentation, Manus Bio provides a sustainable, cost-effective alternative to traditional extraction methods. This approach not only addresses the growing demand for clean-label ingredients but also optimizes supply chain resilience for global consumer goods manufacturers. The company's market position is defined by its ability to bridge the gap between laboratory-scale innovation and large-scale commercial production, effectively disrupting the traditional chemical manufacturing landscape.
How much funding has Manus Bio raised?
Manus Bio has raised a total of $103.8M across 4 funding rounds:
Private Equity
$9.1M
Series A
$19.4M
Debt
$350K
Series B
$75M
Private Equity (2017): $9.1M, investors not publicly disclosed
Series A (2018): $19.4M led by NXT Ventures and Venture Capital
Debt (2020): $350K supported by PPP
Series B (2020): $75M featuring BBGI Public Company Limited
Key Investors in Manus Bio
NXT Ventures
NXT Capital is a prominent provider of structured financing solutions, managing an extensive asset management platform that serves institutional investors including pension plans and insurance companies.
Venture Capital
Ventech is a leading pan-European venture capital firm focused on high-growth startups within the digital economy, deep technology, and enterprise software sectors.
BBGI Public Company Limited
BBGI Public Company Limited is a strategic investor focused on the bio-based industry, supporting the development of sustainable manufacturing and renewable energy solutions.
What's next for Manus Bio?
With the infusion of this recent capital, Manus Bio is poised to accelerate its commercialization efforts and expand its manufacturing footprint. The strategic focus will likely center on scaling production capacity to meet the increasing demand for bio-based ingredients across the cosmetics and agricultural chemical sectors. Furthermore, the company is expected to deepen its research and development pipeline, targeting new molecular structures that can be produced via its proprietary fermentation technology. As the firm transitions into a more mature operational phase, the emphasis will shift toward optimizing unit economics and securing long-term supply agreements with major enterprise partners, thereby cementing its role as a cornerstone of the next-generation bio-economy.
See full Manus Bio company page
